Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ABBOTT INDIA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-23 |
ADCOCK INGRAM Jun-14 |
ABBOTT INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 22,482 | 319 | - | |
Low | Rs | 16,156 | 230 | - | |
Sales per share (Unadj.) | Rs | 2,517.0 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 446.8 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 479.7 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 325.00 | 0 | - | |
Avg Dividend yield | % | 1.7 | 0 | - | |
Book value per share (Unadj.) | Rs | 1,480.5 | 74.5 | - | |
Shares outstanding (eoy) | m | 21.25 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.7 | 2.9 | 265.3% | |
Avg P/E ratio | x | 43.2 | -11.5 | -376.6% | |
P/CF ratio (eoy) | x | 40.3 | -13.9 | -290.6% | |
Price / Book Value ratio | x | 13.0 | 3.7 | 354.0% | |
Dividend payout | % | 72.7 | 0 | - | |
Avg Mkt Cap | Rs m | 410,513 | 46,340 | 885.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 5,636 | 2,908 | 193.8% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 53,487 | 16,016 | 334.0% | |
Other income | Rs m | 1,543 | 112 | 1,375.7% | |
Total revenues | Rs m | 55,030 | 16,128 | 341.2% | |
Gross profit | Rs m | 12,055 | -2,775 | -434.3% | |
Depreciation | Rs m | 700 | 691 | 101.2% | |
Interest | Rs m | 160 | 434 | 36.9% | |
Profit before tax | Rs m | 12,738 | -3,788 | -336.2% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,244 | 237 | 1,370.4% | |
Profit after tax | Rs m | 9,494 | -4,036 | -235.3% | |
Gross profit margin | % | 22.5 | -17.3 | -130.1% | |
Effective tax rate | % | 25.5 | -6.2 | -407.6% | |
Net profit margin | % | 17.8 | -25.2 | -70.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 30,251 | 11,730 | 257.9% | |
Current liabilities | Rs m | 12,060 | 6,600 | 182.7% | |
Net working cap to sales | % | 34.0 | 32.0 | 106.2% | |
Current ratio | x | 2.5 | 1.8 | 141.1% | |
Inventory Days | Days | 87 | 111 | 78.3% | |
Debtors Days | Days | 2 | 124 | 1.7% | |
Net fixed assets | Rs m | 15,135 | 6,838 | 221.3% | |
Share capital | Rs m | 213 | 74 | 285.8% | |
Net worth | Rs m | 31,460 | 12,571 | 250.3% | |
Long term debt | Rs m | 0 | 4,418 | 0.0% | |
Total assets | Rs m | 45,386 | 23,747 | 191.1% | |
Interest coverage | x | 80.7 | -7.7 | -1,043.2% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.7 | 174.7% | |
Return on assets | % | 21.3 | -15.2 | -140.2% | |
Return on equity | % | 30.2 | -32.1 | -94.0% | |
Return on capital | % | 41.0 | -19.8 | -207.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,934 | 1,367 | 653.5% | |
From Investments | Rs m | -1,477 | -420 | 351.9% | |
From Financial Activity | Rs m | -6,387 | 4,009 | -159.3% | |
Net Cashflow | Rs m | 1,070 | 4,957 | 21.6% |
Compare ABBOTT INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: MEDICAMEN BI GUJ.TERC LAB BANDARAM PHARMA PACKTECH JUBILANT PHARMOVA PHAARMASIA
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.